Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial-Reference-Cited by-同舟云学术

Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial

Published:2023-03 Issue:3 Volume:209 Page:532-539
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Hussain Maha¹,Sternberg Cora N.²,Efstathiou Eleni³,Fizazi Karim⁴,Shen Qi⁵,Lin Xun⁶,Sugg Jennifer⁷,Steinberg Joyce⁷,Noerby Bettina⁸,De Giorgi Ugo⁹,Shore Neal D.¹⁰,Saad Fred¹¹

Affiliation:

1. Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois

2. Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, New York

3. MD Anderson Cancer Center, Houston, Texas

4. Institut Gustave Roussy, University of Paris Saclay, Villejuif, France

5. Pfizer Inc., Collegeville, Pennsylvania

6. Pfizer Inc., La Jolla, California

7. Astellas Pharma, Inc., Northbrook, Illinois

8. Sygehus, Lillebaelt, Vejle, Denmark

9. IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy

10. Carolina Urologic Research Center, Myrtle Beach, South Carolina

11. University of Montreal Hospital Center, Montreal, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Link

http://www.auajournals.org/doi/pdf/10.1097/JU.0000000000003084

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Akkermansia muciniphila Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer;Microorganisms;2024-08-12

2. Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis;European Urology Oncology;2024-08

3. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients;The Prostate;2024-05-29

4. Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen–targeted Salvage Surgery;European Urology Oncology;2024-05

5. Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review;Biomedicines;2024-04-08